Harriette Van Spall, MD MPH 🇨🇦

@hvanspall · @hvanspall.bsky.social · joined 16 Sep 2017

Cardiologist @McMasterU, Sr Scientist @PHRIresearch, #Implementation Dir @BaimInstitute, Editor @CircAHA, ChairElect @American_Heart #HF Council, Alum @Harvard

18 480Followers

2 082Following

45 538Posts total

57.4KViews on collected posts

Against accounts of the same size

8 posts from the last 90 days, next to the 10K–100K follower range. ordinary reach for its size, weaker reaction than most.

Median views1 976this account3 808median for 10K–100K

Reach, %10.69%this account12.23%median for 10K–100K

Engagement, %0.56%this account1.37%median for 10K–100K

Metric	This account	Median for 10K–100K	Ratio
Median views per post	1 976	3 808	0.52×
Reach (views ÷ followers)	10.69%	12.23%	0.87×
Engagement rate	0.56%	1.37%	0.41×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

44K28 Aug

2.2K29 Aug

1.8K

1.3K30 Aug

1.4K

2.8K31 Aug

2.1K1 Sep

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.25%28 Aug

0.74%29 Aug

0.28%

0.39%

1.50%30 Aug

1.55%

0.18%31 Aug

1.55%1 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.37%.

What the audience does

Likes67.1%153 in total

Reposts20.2%46 in total

Replies3.5%8 in total

Quotes4.4%10 in total

Bookmarks4.8%11 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

#Hypertension is a leading cause of #CVDs, but under-treated I enjoyed this #ESCCongress discussion w/ Prof @kazemr about his IPD on #BP⬇️ across baseline CV risk BP⬇️ -> consistent RRR across risk categories, w/ variation in safety Will it change practice? @HeartOTXHear 2.1K views · 23 likes · 8 reposts · 2 replies 01 Sep 2026 From 3% to 40% five-year cardiovascular risk and BP lowering across every single decile... At ESC Congress 2026, Prof Kazem Rahimi presented findings from a meta-analysis of ~350,000 participants across 51 randomised trials. Using a cardiovascular risk prediction model, the http 2.8K views · 2 likes · 2 reposts · 0 replies 31 Aug 2026 In this stepped-wedge cluster #RCT of 19🏥s & 67K presentations of chest pain, implementation of a 0/1-hr #hsTpn pathway had non-inferior safety & similar ED LOS as 0/3-hr pathway Fun discussion on trial methods & challenges of #implementation trials #PRESC1SE-MI #ES 1.4K views · 15 likes · 5 reposts · 1 replies 30 Aug 2026 #AMUNDSEN international RCT compared strategy of #PCSK9i (#evolocumab) in cath lab + standard care vs standard care alone in 2166 patients w #ACS undergoing PCI. At 12 mo ⬆️⬆️ in LDL control ↔️ death or CV 🏥 Will it change practice? Listen to prof Monteluscat #ESCcongress h 1.3K views · 13 likes · 4 reposts · 2 replies 30 Aug 2026 🎙️ Dr Van Spall & Dr Jasper Boeddinghaus discuss PRESC1SE-MI from #ESCCongress2026 Implementation of the ESC 0/1-hour pathway achieved: 📊 67,624 patient presentations 📊 Earlier repeat hs-cTn testing (190 min → 86 min) ✅ Non-inferior for death or new type 1 MI 🏥 No reduction 1.8K views · 4 likes · 1 reposts · 0 replies 29 Aug 2026 Can we lower risk after MI by lowering LDL-C earlier? 🎙️ At #ESCCongress2026, Dr Harriette Van Spall speaks with Prof Gilles Montalescot about #AMUNDSEN, a trial evaluating evolocumab before PCI in STEMI and NSTEMI patients. A fascinating discussion on timing, prevention and h 1.8K views · 3 likes · 1 reposts · 0 replies 29 Aug 2026 Oh dear! Wrong take on the data and discordant with the authors’ conclusions in the manuscript. #ESCCongress 2.2K views · 15 likes · 1 reposts · 0 replies 29 Aug 2026 In patients with myocardial scar on #CardiovascularMagneticResonance and left ventricular ejection fraction of 36% to 50%, implantable cardioverter-defibrillator therapy lowered sudden cardiac death vs an implantable loop recorder. #ESCCongress https://t.co/eC4IjRqKrm 44K views · 78 likes · 24 reposts · 3 replies 28 Aug 2026 Thank you @CIHR_IRSC @SCC_CCS for this award which I don’t deserve so early in mid-career, but which I’m grateful for. Indebted to my family, team, collaborators, funders, & to 🇨🇦 for giving this immigrant a chance. So grateful to my nominators. Miss you, dad.. this one’s for 0 views · 262 likes · 22 reposts · 19 replies 26 Jul 2022 📢 Congratulations to Dr. Harriette Van Spall, recipient of the 2022 CIHR-ICRH/CCS Mid-Career Lecturer Award in Cardiovascular Sciences! Learn more: https://t.co/LmcKgqZq6P @SCC_CCS https://t.co/qV5Tm9Zs4r 0 views · 187 likes · 28 reposts · 52 replies 25 Jul 2022